- 1 Differential expression analyses on aortic tissue reveal novel genes and pathways associated
- 2 with abdominal aortic aneurysm onset and progression
- 3 Gerard Temprano-Sagrera MSc (gtemprano@santpau.cat)¹, Begoña Soto MD PhD
- 4 (bsoto@santpau.cat)^{1,2}, Jaume Dilmé MD PhD (jdilme@santpau.cat)^{1,2,3}, Olga Peypoch MD
- 5 (opeypoch@santpau.cat)^{1,2}, Laura Calsina Juscafresa MD PhD (lcalsina@psmar.cat)^{4,5}, David
- 6 Davtian PhD⁶ (2400580@dundee.ac.uk), Lluís Nieto MD (llnietofernandez@gmail.com)⁴,
- 7 Andrew Brown PhD (a.z.t.brown@dundee.ac.uk)⁶, José Román Escudero MD
- 8 (jescuderor@santpau.cat)^{1,2}, Ana Viñuela PhD# (ana.vinuela@newcastle.ac.uk)⁷, Mercedes
- 9 Camacho PhD# (mcamacho@santpau.cat)¹, Maria Sabater-Lleal PhD#
- 10 (msabater@santpau.cat)^{1,8,9}
- 12 #These authors equally contributed as senior authors.
- 14 Affiliations:

13

15

31 32 33

34

39

- 16 1. Unit of genomics of Complex Diseases, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79,
- 17 08041 Barcelona, Spain
- 18 2. Servei d'Angiologia i Cirurgia Vascular i Endovascular, Hospital de la Santa Creu i Sant Pau, Sant Antoni
- 19 Maria Claret 167, 08025 Barcelona, Spain
- 20 3. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERECV), Madrid,
- 21 Spain
- 4. Department of Vascular and Endovascular Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003,
- 23 Barcelona, Spain
- 24 5. Department of Medicine and Surgery, Universitat Pompeu Fabra, Barcelona, Spain
- 25 6. Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee,
- 26 Dundee, DD1 9SY, United Kingdom.
- 7. Biosciences Institute, Faculty of Medical Sciences, University of Newcastle, Newcastle upon Tyne, NE1
- 28 4EP, United Kingdom
- 29 8. Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
- 30 9. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
 - Corresponding author:
- 35 Maria Sabater-Lleal, PhD
- 36 Genomics of Complex Disease Unit, Institut de Recerca Sant Pau (IR SANT PAU)
- 37 St Quintí 77-79, 08041, Barcelona, Spain
- 38 Phone +34932919000; Email: msabater@santpau.cat

ABSTRACT

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Background: Abdominal aortic aneurysms (AAA) are focal dilatations of the abdominal aorta. They are normally asymptomatic and progressively expand, increasing their risk of rupture. Rupture of an AAA is associated with high mortality rates, but the mechanisms underlying the initiation, expansion and rupture of AAA are not yet fully understood. This study aims to characterize and identify new genes associated with the pathophysiology of AAA through differential expression analyses between dilated and non-dilated aortic tissue samples, and between AAA of different diameters. Our study used RNA-seq data on 140 samples, becoming the largest RNA-seq dataset for differential expression studies of AAA. Results: We identified 7,454 differentially expressed genes (DEGs) between AAA and controls, 2,851 of which were new compared to previous microarray studies. Notably, a novel cluster on adenosine triphosphate synthesis regulation emerged as strongly associated with AAA. Additionally, exploring AAA of different diameters identified eight genes (EXTL3, ZFR, DUSP8, DISP1, USP33, VPS37C, ZNF784, RFX1) that overlapped with the DEGs between AAA and controls, implying roles in both disease onset and progression. Seven genes (SPP1, FHL1, GNAS, MORF4L2, HMGN1, ARL1, RNASE4) with differential splicing patterns were also DEGs between AAA and controls, suggesting that splicing differences contribute to the observed expression changes and the disease development. **Conclusions**: This study identified new genes and pathways associated with AAA onset and progression and validated previous relevant roles of inflammation and intracellular calcium regulation. These findings provide insights into the complex mechanisms underlying AAA and indicate potential targets to limit AAA progression and mortality risk. KEYWORDS: Abdominal aortic aneurysm, RNAseq, transcriptomics, differential expression, ischemic time, alternative splicing, allelic specific expression.

BACKGROUND:

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Abdominal aortic aneurysms (AAA) are characterized by a local dilation of the infrarenal abdominal aorta to about 1.5 times the normal adjacent aortic diameter or more than 3 cm in maximum diameter[1]. AAA is accompanied by chronic inflammation, apoptosis of vascular smooth muscle cells and neovascularization[2,3]. Additionally, extracellular matrix degradation, microcalcification, and oxidative stress contribute to the degeneration of the aorta[1,2]. The disease is progressive, and most aneurysms develop without causing symptoms[1]. However, in the event of AAA rupture, mortality rates can reach 80 %[4]. The only effective treatment currently available for AAA is aortic tissue repair, either through open surgery or endovascular repair[1,5]. Some risk factors are known for developing AAA, including age, male sex, smoking, and family history of AAA[1]. Smoking, in addition, is also known to increase the risk of rupture[6]. Additionally, recent genomic studies have revealed 121 loci associated with risk of developing AAA, contributing to the knowledge of the possible pathways leading to this disease[7]. However, there is still an insufficient understanding of the clear mechanisms that underlie the initiation, propagation, and rupture of AAA. The study of gene expression, known as transcriptomics, is a valuable tool for understanding human disease and revealing new therapeutic targets [8,9]. Several studies have been performed to study the differentially expressed genes (DEGs) between dilated aortic tissue and non-dilated control aorta using microarray technology, detecting DEGs especially associated with the immune and inflammatory responses, extracellular matrix remodeling and angiogenesis[10-15]. In the present study, we performed RNA sequencing (RNAseq) of the complete transcriptome in 140 abdominal aortic tissue samples (96 dilated aortas and 44 control aortas from deceased donors) from the Triple A Barcelona Study (TABS) cohort, to identify new DEGs and pathways associated with the pathophysiology of AAA initiation and progression, allowing for a more comprehensive analysis of the transcriptome and becoming the largest RNAseq dataset for AAA tissue. Additionally, we aimed to investigate the differences in alternative splicing patterns in the context of AAA, and the role of genetic variants in gene expression in AAA tissue. The study design is described in **Figure 1**.

RESULTS:

109

110

111

112

113

114

Participants characteristics:

115 **Table 1** shows the participants demographic and clinical data. Aortic tissue samples from 96

116 AAA patients and 44 controls from the TABS cohort were used for RNAseq analysis.

Table 1: Characteristics of study participants

	Controls AAA			Missing
	(N = 44)	(N = 96)	P-value	values (%)
Age (Years)	61.66 (21-82)	70.38 (53-87)	0.0006	O (O)
Sex (Male)	21 (47.73)	92 (95.83)	1.00E-10	O (O)
Smoking (Current)	8 (21.62)	27 (32.14)	0.3378	19 (13.57)
Smoking (Past)	3 (8.11)	42 (50)	2.81E-05	19 (13.57)
Aortic Diameter (mm)	NA	65.57 (38-100.12)	-	0 (0)
Hypertension (Yes)	15 (40.54)	54 (64.29)	0.0256	19 (13.57)
Dyslipidemia (Yes)	10 (27.03)	46 (54.76)	0.0087	19 (13.57)
Diabetes mellitus (Yes)	5 (13.51)	12 (14.29)	1	19 (13.57)
Peripheral arterial disease (Yes)	NA	23 (27.71)	-	57 (59.38)
Other aneurysms (Yes)	NA	25 (29.76)	-	12 (12.5)
Cerebrovascular Disease (Yes)	3 (8.11)	36 (43.9)	0.0003	21 (15)
Cardiovascular Disease (Yes)	1 (3.34)	16 (19.05)	0.0846	27 (19.29)
Chronic obstructive pulmonary disease (Yes)	1 (2.7)	15 (17.86)	0.0481	19 (13.57)

Chronic kidney disease (Yes)	2 (5.4)	17 (20.24)	0.0726	19 (13.57)

Continuous variables are presented as mean (range), and categorical variables are presented as

%. Two-sample t-tests and chi-squared tests were used to compare the means of continuous

phenotypes and the distribution of categorical phenotypes, between AAA and control groups, respectively. Missing values were excluded from the calculations of each variable. Hypertension was defined based on clinical history and the use of antihypertensive medication. Dyslipidemia was diagnosed through clinical history and the use of hypolipidemic medication. Diabetes mellitus was identified by clinical history and the use of insulin or oral hypoglycemic medications, without differentiation between type 1 or type 2. Peripheral arterial disease was assessed based on clinical symptoms and clinical history. Other aneurysms included thoracic and visceral aortic aneurysms, iliac artery aneurysms, and popliteal artery aneurysms, and were diagnosed using computed tomography or ultrasound. Cerebrovascular diseases were determined by a history of transient ischemic attack or stroke. Cardiovascular diseases were assessed by history of acute myocardial infarction or angina pectoris, or admission with clinical symptoms, electrocardiogram changes, or a positive enzymatic curve diagnosed by a cardiologist. Chronic obstructive pulmonary disease was identified based on clinical history. Chronic kidney disease was assessed by clinical history. We examined demographic and clinical variables between AAA and controls to determine whether these might influence our expression levels differences. We found significant differences in sex (Additional file 1: Figure S1A), age (Additional file 1: Figure S1B), smoking status, and the prevalence of hypertension, dyslipidemia, cerebrovascular disease, and chronic obstructive pulmonary disease between AAA patients and controls. In relation to smoking status (N = 122), which is a known risk factor for AAA development and rupture, 70.3 % of controls were never smokers, compared to 17.86 % of AAA patients. Among current and past smokers, there were also differences, with 50 % of former smokers and 32.14 % of current smokers in AAA, compared to only 8.11 % and 21.62 % respectively, in the controls (Additional

117

118

119

120

121

122

123

124

125

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

file 1: Figure S3C). We adjusted our regression analyses for age and sex, acknowledging their potential influence on expression level differences. <u>Differential expression analyses between AAA and controls:</u> The analysis of differential expression between aortic samples from 96 AAA patients and 44 controls revealed 7,454 genes displaying significant differences in expression (adjusted p-value < 0.05) (Additional file 1: Figure S2A and Additional file 2: Table S1). This number exceeds by 26.57 % the previous DEGs identified in comparable analyses using microarray technologies[10-15]. Using GO and KEGG enrichment analyses, we found a total of 1,152 and 89 enriched terms, respectively (Additional file 1: Figure S3A and Figure S4A). The complete results of the enriched terms for GO and KEGG are shown in Additional files 3 and 4: Tables S2 and S3. To better characterize the biological processes associated with the DEGs in the enrichment analysis, we performed a cluster analysis of GO pathways. We found that most of the DEGs were associated with the immune system: regulation of mononuclear cell proliferation, leukocyte chemotaxis, regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains, mast cell degranulation, major histocompatibility complex (MHC) class II protein complex, positive regulation of T cell activation, and CD4-positive alpha-beta T cell differentiation (Figure 2A). Other represented metabolic pathways were related to sequestering of calcium ion, regulation of actin filament length and adenosine triphosphate (ATP) synthesis coupled electron transport (Figure 2A). While these analyses corroborated previous associations with inflammatory, actin filament regulation and intracellular calcium regulation processes, the ATP synthesis regulation pathway was a new differential expressed pathway in AAA tissue. Control aortic samples from deceased organ donors have been used by us and others [10-13,15]. To account for differences in gene expression between AAA and control tissue that

could be attributed to ischemic time (time between the donor's death and sample collection

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

when blood flow is interrupted), we removed 10,737 DEGs associated to ischemic time in the GTEx aorta samples (N = 387)[16] from the total DEGs found between AAA and controls, leaving 3,002 DEGs (Additional file 1: Figure S2B and Additional file 5: Table S4). We then performed a new enrichment analysis and identified 424 enriched GO terms and 65 KEGG pathways (Additional file 1: Figure S3B and Figure S4B) (Complete results are available at Additional files 6 and 7: Tables S5 and S6, respectively), which represented removal of 728 and 24 pathways susceptible of being caused by ischemic time, respectively. Cluster analysis of GO enriched terms confirmed identified clusters related to the regulation of calcium ion retention, ATP synthesis coupled electron transport, and immune response centered on T cell activation (MHC class II protein complex, positive regulation of T cell activation). On the other hand, other clusters also associated with the immune system were no longer represented (regulation of mononuclear cell proliferation, leukocyte chemotaxis regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains, CD4-positive, alpha-beta T cell differentiation, mast cell degranulation) together with the regulation of actin filament length (Figure 2B). By accounting for genes whose expression was altered by ischemic time, we identified a set of genes that are less likely to be affected by the experimental limitations of these types of studies. Vascular inflammation has been previously associated to AAA development and progression[17,18]. Even in our most stringent analysis, which removed pathways possibly caused by ischemic time, there was a notable enrichment of pathways associated with the immune response. Consequently, we decided to investigate the influence of the inflammatory infiltrate on AAA by comparing the abundance of 22 immune cell types from gene expression profiles between our AAA and control samples. After correcting for multiple testing, we found significant differences on the abundances of CD8 T-cells, natural killer (NK) resting cells, and dendritic activated cells (Figure 2C). AAA samples had a higher proportion of CD8 T-cells, while controls had more NK resting cells and dendritic activated cells. **Table 2** provides a summary of the three cell populations with the highest and lowest presence in each group. The findings support the previously reported involvement of CD8 T-cells and NK cells in AAA.[17,18] The lower levels of dendritic cells detected in AAA were unexpected, as previous studies found significantly higher levels of dendritic cells in AAA samples compared to controls[19].

Table 2: Summary of the three most and least prevalent cell populations in AAA and controls.

Cell Populations (AAA)	Percentage (%)	Cell Populations (Controls)	Percentage (%)
Plasma B cells	9.46	Resting mast cells	12.34
M2 macrophages	8.68	Resting memory CD4 T cells	8.31
Resting mast cells	6.99	M2 Macrophages	8.23
M1 macrophages	1.43	Eosinophils	2.03
Eosinophils	1.37	T cell follicular helper cells	1.94
Activated dendritic cells	1.13	M1 Macrophages	1.45

Study of alternative splicing:

The relevance of alternative splicing in the development of diseases, such as cancer, neurological, and cardiovascular diseases has been well-established for years.[20] However, capturing the complexity of alternative splicing has been challenging. With the recent improvements in sequencing techniques it is now possible to study alternative splicing in more depth.[20] We investigated alternative splicing patterns between the AAA and control groups to identify specific splicing patterns associated with AAA. We identified 15 significant alternative splicing events on eleven unique genes (FHL1, GNAS, ASAH1, SPP1, ARL1, MORF4L2, CYCS, HMGB1, HMGN1, SELENOP, RNASE4) between AAA and controls. The analysis revealed that, as anticipated, the number of altered alternative first exon events was more represented than any other splice event among AAA and control samples (Figure 3A), consistent with

previous work suggesting that it is the most frequent splice event in the human genome[21] (Complete results are available in **Additional file 8: Table S7**). A functional enrichment analysis was conducted on the eleven genes with significant alternative splicing events, but no significantly enriched metabolic pathways were found. Interestingly, seven out of the eleven genes were also differentially expressed between AAA and controls, suggesting that the expression of specific splicing variants could be altered in AAA (**Figure 3B**).

<u>Differential expression analysis by aortic diameter:</u>

The diameter of AAA is a significant risk factor for rupture. We analyzed the DEGs by diameter to identify alterations in gene expression throughout the progression of the disease. We observed a total of 32 DEGs among aneurysms of varying diameters (N = 84), although no enriched pathways were identified (Additional file 1: Figure S2C and Additional file 9: Table S8). Of the 32 DEGs by diameter, eight were also DEGs between AAA and controls (Figure 3C), suggesting that these eight genes are relevant for disease formation and also during disease progression.

Allelic specific expression:

We investigated the potential effect of AAA-associated genetic variants on gene expression in diseased tissue by studying allele specific expression in twelve AAA samples with available genetic data. On average, we identified 529 genes with significant allele specific expression (adjusted p-value < 0.05) in the twelve AAA samples. Among these genes, 90 exhibited significant allele specific expression in more than five of the twelve AAA samples. Additionally, to determine whether these associations were related to AAA or were characteristic of the aortic tissue, we compared allele specific expression patterns between our AAA samples and 387 GTEx aortic samples, used as controls. The comparison between AAA and control samples identified 1,815 genes with significant differences in the allele specific expression patterns (adjusted p-value < 0.05) (Figure 4A). An enrichment analysis on GO terms for these 1,815

genes revealed 91 enriched pathways. The posterior cluster analysis revealed three clusters strongly related to the immune system: MHC protein complex, positive regulation of T cell-mediated cytotoxicity, and regulation of T cell activation (Figure 4B). The association between the immune system and AAA was also observed in the differential expression analysis between AAA samples and controls, validating the robustness of these results.

Finally, among the 90 genes that exhibited significant allele specific expression in more than five AAA samples, we selected those that also showed significant differential allelic specific expression analysis between AAA and GTEx control samples, and those present in loci identified in the largest genome-wide association study (GWAS) on AAA risk[7], in order to identify haplotypes associated with AAA risk. Among the selected genes, SNURF was the only gene that also presented differential allele specific expression patterns between AAA and control tissues, and SPP1 and THBS2 were prioritized based on their presence in a locus identified in the previous GWAS on AAA. This allowed to hypothesize that the presence of particular genetic haplotypes in these three genes determined their differential expression associated with risk of AAA.

DISCUSSION:

This study analyzes differential expression between AAA aortic tissue samples and control aortic samples using whole transcriptome data obtained through RNAseq. In addition, we studied the effect of ischemic time on gene expression, to obtain a more credible list of genes associated with AAA development. Using our RNAseq data, which provides superior alternative splicing analysis compared to microarrays[22], we conducted a novel exploration of alternative splicing between AAA and control samples, to identify potential causes of the observed differential expression. Furthermore, we analyzed the differential expression between AAA of different diameters to study the genes altered during disease progression. Finally, we analyzed

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

allele specific expression to gain insights into how genetic variants impact expression in the diseased tissue. <u>Study of ischemic time-independent pathways involved in AAA development:</u> Clustering analysis with the enriched pathways after accounting for the ischemic time effect revealed a strong association with MHC class II protein complex, positive regulation of T-cells, and intracellular calcium ion regulation. Additionally, we have for the first time identified the regulation of the ATP synthesis pathway in a differential expression analysis of aortic samples. While the detection of the ATP synthesis regulatory pathway is novel, it is in line with previous work associating mitochondrial disfunction and AAA [23,24]. On the other hand, previous differential expression studies in microarrays between AAA and control aortic tissue have consistently found associations of immune system pathways with AAA.[10-13,15] Our results confirm these associations and demonstrate that these are independent of the ischemic time, which is a confounder factor in most studies using donor samples. Finally, the regulation of intracellular calcium was previously detected in one study of differential expression between dilated and non-dilated aortic samples[11]. Our analyses confirm that this association is independent of ischemic time. We identified for the first time several enriched signaling pathways, with a large presence of genes that code for subunits of complexes I (NADH ubiquinone oxidoreductase)), III (Ubiquinolcytochrome c reductase) and IV (cytochrome c oxidase)) of the electron transport chain. Our results indicate that 88 % (22 / 25) of the DEGs coding for the subunits of the complexes that form the electron transport chain are expressed to a lower extent in AAA, suggesting a lower synthesis of ATP in AAA tissue. Mitochondrial dysfunction has previously been studied in the development of AAA[23,24] and other cardiovascular diseases[25] due to its key role in some of the cellular alterations characteristic of cardiovascular diseases, including excessive production of reactive oxygen species, energy depletion, endoplasmic reticulum stress, and

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

activation of apoptosis. However, this is the first time that these metabolic pathways have been characterized in a DEGs study of AAA, confirming the role of mitochondrial dysfunction on AAA. Among the genes present in all the enriched signaling pathways related to intracellular calcium regulation, APLNR[26], F2R[27], GPER1[19], JPH2[28], PKD2[29] and THY1/CD90[30] have already been investigated for their role in AAA. However, six additional genes are present in all pathways: ABL1, CALM1, CALM2, RYR2, SRI and CD19. Except for CALM2, all of them have been previously identified as DEGs in previous microarray studies between AAA and control samples[10-12,15], but none of these genes have been further investigated in either functional or epidemiological studies. These genes are closely related to intracellular calcium metabolism. ABL1 participates in both the release of stored intracellular calcium and extracellular calcium entry[31]. CALM1 and CALM2 code for two isoforms of the calmodulin protein, which plays a crucial role in the contraction of vascular and cardiac tissue through the detection of intracellular calcium[32]. RYR2 is mainly expressed in cardiac tissue and codes for the main regulator of sarcoplasmic calcium release[33]. SRI codes for the main binding protein of the RYR2 gene product[34]. The comparison between our AAA and control samples shows a downregulation of all these genes, suggesting a decrease in intracellular calcium levels in smooth muscle cells, consistent with loss of vascular contractility in the dilated aorta[35]. On the other hand, we observed upregulation of the CD19 gene in AAA. The activation of the surface protein encoded by CD19 triggers the release of intracellular calcium, which contrasts with the previous results[36]. However, CD19 is also a biomarker of B-cell development [36] which also play a key role in the development of AAA[37]. Among the pathways that were previously identified in differential expression analyses between AAA and control tissue is inflammation. There is a widely studied inflammatory component in AAA development involving both, adaptative and innate immune responses [17,18]. The presence of inflammatory infiltrates in AAA tissue have been widely

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

demonstrated, which play a key role in the development of the disease[17,18]. The results of our cluster analysis also corroborated the association with the immune system after accounting for ischemic time, highlighting the key role of T cells on AAA development[38,39]. To better understand the effects of the inflammatory infiltrate in AAA development, we compared the proportions of inflammatory infiltrates between AAA and control samples. Some previous studies have analyzed the inflammatory infiltrates in AAA tissue[15,19,40]. In one study[15], immune cell proportions were estimated in AAA tissue layers (media and adventitia), without comparing with controls. Our results strongly corroborate their findings, suggesting that plasma B cells and M2 macrophages were the two most represented cell populations in both layers, and M1 macrophages, eosinophils, and activated dendritic cells were among the least represented cells in both layers. Surprisingly, resting mast cells emerged as our third most represented cell group, while in the layer-specific analysis, mast cells represented a small percentage of the total inflammatory cells. This contrasts with another study that compared whole-tissue samples between AAA and controls[19], where resting mast cells were among the most frequent cell groups in AAA samples. In addition, our results align with this study in detecting higher proportions of CD8 T-cells and lower proportions of resting NK cells in AAA samples. However, a discrepancy was noted in the levels of activated dendritic cells, which were more present in controls in our study but slightly higher in AAA samples in the previous work. Additional single-cell data demonstrated a higher proportion of T follicular helper cells and lower proportions of M1 and M2 macrophages in AAA samples compared to controls[40]. To rule out the effect of death as potential cause of variability, we used a reference work that evaluated the effect of death in blood samples,[41] which found higher levels of resting NK cells and CD8 T-cells in post-mortem samples. These results suggest that the increase in CD8 Tcells levels in AAA tissue could be even greater than the one we observed, and that the greater presence of NK resting cells in control samples could be due, in part, to their origin from organ

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

donors. Consistent with this hypothesis, previous studies have shown that levels of NK cells are higher in the peripheral blood of AAA patients compared to controls,[42] and that these cells play a role in the development of the disease[18]. These results also suggest the existence of a highly cytotoxic environment led by CD8 T-cells in AAA tissue. The lower levels of activated dendritic cells in the AAA samples compared to the controls was unexpected, given their established role as AAA inducers[17,19]. These results suggest that, although dendritic cells may participate in the development of AAA, they are not part of the inflammatory infiltrate. Study of alternative splicing between AAA and controls: This is the first study to elucidate the role of splicing in AAA development. We compared splice events between AAA and controls and identified eleven genes (SPP1, FHL1, GNAS, MORF4L2, HMGN1, ARL1, RNASE4, ASAH1, CYCS, HMGB1, SELENOP) with differentially represented splicing variants. We compared the splice events types identified in our comparison between AAA and controls samples with the presence of splicing events in the whole genome [21] and the observed proportions were comparable to the expected values genome-wide. The most frequent splicing types were alternative first exon (60 %) and skipping exon (20 %), while the least frequent were alternative 5' splice-site (13.3 %) and mutually exclusive exon (6.67 %). On the other hand, it was surprising that our results did not include alternative last exon, alternative 3' splice-site, and retained intron, despite their considerable genome-wide frequencies (10.72 %, 9.2 % and 3.54 %, respectively). This may be due to the limited sample size, as only 15 events were identified. We observed seven genes that showed differential expression between AAA and control samples and had a splicing variant significantly more represented in AAA or controls (SPP1, FHL1, GNAS, MORF4L2, HMGN1, ARL1, RNASE4), indicating that splicing differences could be explaining the observed differential expression. Among these genes, SPP1 and FHL1 have been

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

previously characterized in relation to AAA[43,44], whereas GNAS is a new DEG identified between AAA and control tissue. The evidence of differential splicing events validates GNAS as a new robust DEG between AAA and control tissue, and suggests that alternative splicing in this gene explains the differential expression and its implication to AAA. Finally, MORF4L2, HMGN1, ARL1 and RNASE4 although they have been identified in previous differential expression studies in relation to AAA[10-15], their specific role in AAA has not been studied. For these genes, our results contribute to understand the molecular mechanism leading to differential expression in AAA tissue. SPP1 codes for the osteopontin protein, an important regulator of inflammation that has described functions in cardiovascular diseases[45]. SPP1 is more expressed in AAA tissue than controls, both in animal models and in humans, and it participates in AAA-associated extracellular matrix degradation[46,47] through the nuclear factor kappa B signaling pathway. It is also known that the SPP1 gene undergoes splicing and gives rise to 3 distinct isoforms osteopontin a, osteopontin b and osteopontin c, with specific characteristics, which have not been characterized in AAA. Consistent with previous data, our results found increased expression in AAA tissue, and identified for the first time that that skipping of exon 3 on SPP1 gene is more frequent in AAA than in controls, suggesting that this form of alternative splicing may be important for the development of AAA. FHL1 codes for a protein that is highly expressed in skeletal and cardiac muscle. FHL1 has been shown to be a promising blood biomarker for human ascending thoracic aortic aneurysm as a modulator of metalloproteases.[44] Our findings, and those obtained in previous microarray studies[10-13,15], indicate that FHL1 levels are lower in AAA than in controls. We have detected for the first time that an alternative 5' splicing-site form in this gene occurs more frequently in the control group, suggesting that AAA tissue would have reduced expression of this alternative isoform and reduced levels of FHL1, leading to higher risk of AAA development.

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

Although not previously found in transcriptomic studies, mutations in the GNAS gene have been studied in mice for their effect promoting AAA[48]. GNAS codes for the alpha subunit of the heterotrimeric G stimulatory protein (Gs α). Gs α may play a protective role in AAA development through regulation of vascular muscle tissue and is considered a potential therapeutic target[48]. Consistent with this protective role, our results confirmed lower expression GNAS levels in AAA. Moreover, our results add a mechanistic insight by revealing an alternative first exon splicing variant that occurs more frequently in controls and that could increase expression levels of the final protein and protect against AAA. MORF4L2 and HMGN1 are DNA repair related genes, which had significantly lower and higher expression levels in AAA tissue compared to control tissue, respectively. MORF4L2 has been associated with atheroma plaque progression in atherosclerosis[49]. Both genes present alternative splicing events that are less frequent in AAA tissue. Further work to elucidate the specific role of these genes in the risk of AAA development is warranted. Genes associated with AAA onset and progression: We identified eight genes (EXTL3, ZFR, DUSP8, DISP1, USP33, VPS37C, ZNF784, RFX1) that showed differential expression between AAA and control tissues, and also differential expression in AAA tissues of different diameters. Among these, EXTL3, ZFR, DUSP8, and DISP1 have been previously identified as DEGs between AAA and controls but their role in AAA progression is novel.[10–15], and USP33, VPS37C, ZNF784 and RFX1 are novel DEGs. This could indicate that the genes may have a role beyond the disease onset and could be potential therapeutic targets to halt aneurysm expansion. Therefore, the potential contribution of these genes to the development of AAA needs to be thoroughly investigated. Among the genes with higher expression at larger diameters, USP33 encodes a deubiquitinating enzyme that has been associated with the development of hypertension[50], a known risk factor for AAA[51]. Proteins with deubiquitinating functions have been proposed

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

as possible candidate genes for the treatment of AAA and other cardiovascular diseases[52]. Additionally, USP33 promotes the stabilization of beta2-adrenergic receptors, which promote vasodilation in smooth muscle[53]. We observed an increase in USP33 expression with increased AAA diameter, which is consistent with the functionality of beta2-adrenergic receptors. These results suggest that the USP33 gene may be a potential candidate for the treatment of AAA. Among the genes that exhibit lower expression levels with larger diameters, we highlight DUSP8 and RFX1. DUSP8 is a phosphatase that negatively regulates the MAP kinase pathway, which is linked to cell differentiation and proliferation[54]. Previous studies have shown that DUSP8 expression levels are downregulated in mouse models of aortic dilatation[55], and the dual specificity phosphatase 8 protein (DUSP8) acts as a regulator of cardiac dynamics[54]. Our findings align with those obtained in the animal model of aortic dilatation, suggesting that DUSP8 may be a potential candidate gene for treating AAA by regulating both aortic dilatation and the immune system. RFX1 encodes a transcription factor that regulates genes involved in MHC class II[56]. In a previous bioinformatics study using microarray data, RFX1 was identified as a transcription factor that could potentially regulate DEGs between AAA and controls through its downregulation[57]. Previous research has shown that a decrease in RFX1 expression leads to activation of CD14⁺ monocytes in CAD patients[58]. Furthermore, CD14 protein plays a crucial role in recruiting macrophages during the early stages of AAA, and knockout mice for CD14 gene have been shown to resist the formation of AAA in two different models[59]. Finally, our expression results indicate that CD14 is upregulated in AAA patients compared to controls (FDR P-value = 0.002). In conclusion, these results suggest that low expression levels of the transcription factor RFX1 may lead increased CD14 expression, which plays a crucial role in the development and progression of AAA by recruiting macrophages.

Two previous studies have considered the diameter of AAA in differential expression analyses with aortic tissues. The first study[10] compared gene expression between small (n = 20) and large AAA (n = 29) with controls, but did not compare AAA of varying diameters. The second study[15] performed a correlation analysis on each gene between the diameter growth rate and gene expression in individuals (n = 24) with two aortic measurements, distinguishing between the media and adventitia aortic layers but did not identify any significant genes after multiple testing correction. The larger sample size in our study have enabled to identify for the first time genes that are associated to aneurysm progression, which could be potential therapeutic targets.

<u>Identification of haplotypes associated with AAA risk:</u>

We performed a clustering analysis of enriched biological pathways with the 1,815 genes with significant differences in the allele specific expression patterns between AAA and controls. The cluster analysis revealed a strong association with immune system pathways, particularly those associated with T cells. These results are consistent with the clustering analysis of DEGs between AAA and controls and demonstrate how specific haplotypes determine the differential expression of genes associated with AAA in the diseased tissue. By combining allele specific expression information on AAA samples with the allelic specific expression results between AAA and controls, along with information from a previously published GWAS[7], we explored the associations between genetic variants associated with AAA risk and gene expression. This approach aimed to unravel the association between genetic haplotypes and gene expression as determinants of AAA risk.

SNURF is the only gene that showed significant allelic specific expression in more than five of the twelve studied individuals with AAA and differential allelic specific expression patterns between AAA and controls suggesting the existence of a specific haplotype associated with less expression in AAA and leading to higher risk of AAA. SNURF codes for an open reading frame of

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

the SNRPN gene, with which it forms a bicistronic gene[60]. Both genes exhibit significantly lower expression in AAA than in controls in our data. Moreover, we observed that rs705 single nucleotide polymorphism (SNP) (minor allele frequency (MAF) (C) = 0.45) determined SNURF expression in eight out of twelve AAA samples, where the T allele was associated with double expression amounts compared to the C allele. Additionally, rs705 is an eQTL in blood of the SNRPN gene. Although causality cannot be derived from these results, these results suggest a possible effect of the haplotype containing the rs705 T allele on this locus on SNURF expression, resulting in higher risk for AAA development. Among the genes with significant allele specific expression in the twelve analyzed AAA samples that did not exhibit significant allele specific expression patterns between AAA and control groups in our analyses, we selected those that were part of a locus associated to AAA in the most recent GWAS on AAA risk[7]. THBS2 encodes for thrombospondin 2, a protein that regulates cell-cell and cell-extracellular matrix interactions and has been studied in relation to multiple cardiovascular diseases[61]. THBS1, a member of the same family, has been identified as a regulator of AAA in animal models[62]. Our allele specific expression results suggest that the expression of this gene could be associated with AAA development, supporting the implication of the gene in AAA risk. Two common genetic variants (rs58023137 (MAF (T) = 0.22) and rs9505895 (MAF (A) = 0.2)) were identified in previous GWAS studies[7] and in our allele specific expression results. For both variants, the GWAS risk allele was associated with higher expression gene levels in one individual with AAA. Additionally, these two variants were also eQTLs in aortic tissue regulating THBS2 gene expression, confirming the known association between thrombospondin and AAA[7], and demonstrating the presence of risk haplotypes associated to increased expression and risk of AAA. Regarding the SPP1 gene, we found six genetic variants (rs35893069 (MAF (T) = 0.1), rs6839524 (MAF(G) = 0.12), rs4754 (MAF(C) = 0.28), rs1126616 (MAF(T) = 0.27), rs1126772 (MAF(G) = 0.28)

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

0.21), rs9138 (MAF (C) = 0.22)) with allele specific expression among the twelve AAA samples. As previously discussed, the SPP1 has been associated to AAA risk due to the role of the protein osteopontin, which it encodes, in the degradation of the extracellular matrix that is characteristic of AAA[46,47]. However, none of the six genetic variants were found to be significant in the previous GWAS[7], and therefore no association with allelic expression could be established. Strengths and limitations and comparison with previous studies This is one of the largest studies of differential expression between AAA tissue samples and controls. However, due to the difficulty in obtaining aortic tissue samples, the sample size is still limited compared to transcriptomic studies in more accessible tissues, which may have limited our power. Previous studies comparing transcriptomics between AAA and control samples have been limited to the use of expression microarrays[10-15]. In this study, we used RNAseq to obtain transcriptomic information. RNAseq provides greater sensitivity, a wider range of detection of both high and low expression genes, and is not limited to microarray probes[9,63], which allowed us to detect more DEGs. Additionally, RNAseq technology allowed for a more precise study of alternative splicing compared to microarrays. Accounting for ischemic time enabled us to more accurately identify biological processes associated to AAA, thereby minimizing differences in sample origins between AAA and controls. At the same time, despite ensuring more robust findings, the elimination of these genes could have been too rigorous and imply the loss of some biological pathways associated with AAA that, at the same time were affected by ischemic time. The significant phenotypic differences in age and sex between individuals recruited as AAA and controls are a limitation of the study. Moreover, the analyses of the allele specific expression are limited by the small sample size (n = 12) and the requirement for the individuals to be heterozygous in order to study the genetic variants. Therefore, further validation is necessary.

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

However, this is the first study analyzing allele specific expression in AAA and our results emphasize the value of this new dataset combining genetic and expression data for the study of AAA. Finally, the conclusions presented in this article are based on the results obtained from a cohort of European- ancestry individuals only. Further analyses in different ancestries will determine the generalization of these results. CONCLUSIONS Our analysis of the whole transcriptome has enabled us to identify numerous novel genes that were not previously detected in microarray studies. Additionally, our efforts to account for the impact of ischemic time have provided more robust implicated biological pathways that lead to AAA development. Among these pathways, ATP synthesis regulation (i.e. genes encoding subunits I, III and IV of the electron transport chain), has been associated for the first time in transcriptomic studies of AAA tissue, although this pathway was previously studied in relation to AAA in previous studies[23,24]. Additionally, the study of differential splicing processes between AAA and controls have revealed novel molecular processes involving already known genes in relation to AAA, such as SPP1, FHL1 or GNAS. The study also analyzed the differential expression of genes in individuals with AAA of different diameters, providing valuable insights into the underlying molecular mechanisms contributing to AAA progression. Further research on these genes may lead to potential treatments against aneurysm expansion, which increases the risk of rupture. Finally, the analysis of differential allele specific expression in twelve AAA has allowed the identification of haplotypes associated with expression of certain genes and AAA risk, providing evidence for their involvement in disease, and shedding light into the molecular mechanism. Overall, this study provides a comprehensive exploration of AAA expression patterns, revealing key insights into the pathophysiology of AAA initiation and progression. RNAseg was used to conduct one of the largest differential expression analyses to date, uncovering numerous genes associated with AAA. Our consideration of ischemic time and AAA diameter improved the precision in identifying biological processes associated with AAA onset and progression. Furthermore, our analysis of differential allele specific expression has identified genetic haplotypes that influence gene expression on AAA tissue, which advances our understanding of AAA genetic background. These findings contribute to future research and potential advances in precision medicine to reduce AAA progression and mortality risk.

METHODS:

Subjects:

We used a total of 140 human abdominal aortic samples from 96 patients diagnosed with infrarenal AAA and undergoing open surgery for AAA repair at *Hospital de la Santa Creu i Sant Pau* and *Hospital del Mar* (Barcelona) and 44 controls. The study participants were obtained from TABS cohort, which includes genomic, transcriptomic, clinical, and maximum aneurysm size data, from AAA patients and healthy individuals. Maximum aortic diameters were obtained from computed tomography or ultrasound images. Genomic data were obtained through genotyping using the Infinium Global Screening Array-24 v2.0 from Illumina (San Diego, California) (coverage 665,608 variants) and imputation to the TOPMED Reference Panel. Only variants with imputation quality > 0.3 were used for the allele specific expression analyses. Healthy abdominal aortas were obtained from 21 male and 23 female multiorgan donors (Table 1).

Sample processing:

A portion of tissue sample was placed in RNAlater solution (Qiagen GmbH, Hilden, Germany) and stored for 24 hours at 4 °C before long-term storage at –80 °C until further processing. For RNA isolation, tissues were then homogenized in 1 ml Trizol (ambion, Carlsbad, CA) in the FastPrep-24 homogenizer and Lysing Matrix D tubes (MP Biomedicals, Solon, OH) and RNA was

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

purified using PureLink RNA Mini Kit (Invitrogen, Carlsbarg) following the manufacturer's recommendations. RNA concentration was measured using Nanodrop 200 (Thermo Scientific). RNA integrity was assessed on Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). RNA integrity number (RIN) was recorded and only samples with a RIN higher than 6 were used. RNA sequencing: We performed sequencing analyses using Illumina NovaSeq 6000, with a read length of 150 bp and paired-end sequencing. Two sequencing runs were performed to reduce the variability of the technical variables. First, AAA and control samples were randomized between sequencing plates. Second, only AAA were sequenced with as little technical variability as possible. In all sequencing runs, a minimum of 30 million reads were required, repeating the sequencing on a new plate if this limit was not reached. Alignment, quantification, and quality control: We used STAR v.2.5.3a[64] to perform the alignment on the reference genome version GRCh38 and we then used RSEM v1.3.0[65] for gene quantification. For both analyses, we used gene models from GENCODE v26 gene annotation file[66]. In total, 58,219 genes were quantified. Of these, we selected protein coding genes and long non-coding RNA (IncRNA) genes that had been either experimentally validated (level 1 annotation) or manually annotated (level 2 annotation)[66], resulting in 27,290 genes (19,777 protein-coding and 7,513 lncRNA) for further analyses. Gene quantifications were expressed as Transcripts Per Million (TPMs), which were obtained by normalizing for gene length first, and then for sequencing depth. This ensured that the sum of all TPMs in each sample was the same, facilitating the comparison between samples. All samples reached a minimum of 10 million reads aligned to the reference genome with STAR (Additional file 1: Figure S5A-5B)[64].

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

As part of the quality control, we also checked that the reported sex of the samples matched the biological sex of the sequenced data. To do this, we compared the expression levels of the XIST gene, which regulates the X chromosome inactivation mechanism in females and has null expression in males, with the expression of male exclusive genes, calculating an average expression of Y chromosome genes. One sex mismatch sample was eliminated from the study (Additional file 1: Figure S5C). Differential expression analysis: Before conducting differential expression analyses, we normalized the TPMs counts using quantile normalization and removed lowly expressed genes by removing genes with less than 0.5 TPMs in more than 50% of the samples. For the comparison of AAA against control samples, we kept 14,675 genes and removed 12,615 genes. For the comparisons among AAA using the AAA-only sequencing panel, we kept 14,779 genes and removed 12,511 genes. To evaluate the impact of technical covariates on the results, we performed a Principal Components (PC) Analysis on all samples and tested the correlation between the PC Analysis and all the technical covariates. Technical covariates that had significant correlations (p-value < 0.05) with the first four PC were included in the analyses as fixed effect covariates. Additionally, all comparisons were adjusted for age and sex. To preserve the regulatory effects that act through smoking, we did not include smoking as a covariate (Additional file 10: Table S9). First, we calculated DEGs between AAA and controls using a linear regression, including age, sex, flow cell type, flow cell lane, GC mean content (GC mean), RIN, percentage of RNA fragments > 200 (DV200), and Qubit as covariates. Date of creation of the library was not included due to its high correlation with the case/control variable (Pearson's correlation = -0.74) (Additional file 1: Figure S6A-6B)). Second, we calculated DEGs between aneurysms of varying diameter using a linear regression, including age, sex, date of creation of the library, batch number, GC mean, RIN, DV200 and Qubit. We corrected for multiple testing in both

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

analyses using Benjamini-Hochberg false discovery rate (FDR) method and considered significant DEGs those with an adjusted p-value below 0.05[67]. We then performed a linear regression model to identify genes whose expression could be altered by ischemic time, using ischemic time information on artery aorta tissue samples from GTEx V8 data[16]. We corrected the linear regression model for age, sex, RIN, type 2 diabetes, body mass index, autolysis score, center, sequencing protocol, sequencing platform, and genotyping PC. To determine the genes affected by ischemic time, we corrected for multiple testing and selected genes with an FDR-adjusted p-value lower than 0.05[67]. All analyses were performed in R. Enrichment analysis: After identifying DEGs between AAA and control samples and between AAA of varying diameters, we performed enrichment analyses using the R package 'clusterprofiler' [68,69] on the Gene Ontology (GO) databases for Biological Process, Cellular Component and Molecular Function, as well as the Kyoto Encyclopedia of Genes and Genomes (KEGG)[70]. We corrected for multiple testing using the Benjamini-Hochberg FDR method and identified significantly enriched pathways with an adjusted p-value below 0.05[71]. We used 'aPEAR' [72] to perform a cluster analysis of redundant pathways with a minimum cluster of size of 15 and hierarchical clustering. The enriched pathways and genes were visualized using 'enrichplot' [73]. Study of the inflammatory infiltrate: We investigated the differences in the proportions of inflammatory infiltrates between AAA and control samples using CIBERSORTx[74]. CIBERSORTx compares RNAseq data with a reference expression database of selected cell types, to estimate the proportion of each cell type. The residuals of our RNA-seq data were calculated using a linear regression that included all covariates except the status variable. We used the residuals and the 'lm22' signature matrix, that contains expression data of 547 genes in 22 inflammatory cell types from microarray

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

studies, and can be used to distinguish inflammatory cell populations in RNA-seq data[74]. We conducted a t-test to compare the proportions of each cell type between AAA and controls. A p-value threshold corrected by multiple testing using Bonferroni for the number of cell types was set at p-value $< 2.27 \times 10^{-3} (0.05 / 22)$. Alternative splicing: We used the SUPPA2 software to identify differences in splice events between AAA and control tissue samples. SUPPA2 can identify seven different splice events including skipping exons, mutually exclusive exons, alternative 5' or 3' splice sites, retained introns, and alternative first or last exons. Based on gene annotation from GENCODE v26,[66] we computed the proportion of splice inclusion for the TPMs counts in each splice event by dividing the number of TPMs of one form of the event by the total number of TPMs. Finally, the magnitude of splicing change was calculated by subtracting the proportion of splice inclusions between AAA and controls. Significant alternative splicing events were selected based on a magnitude of splicing change higher than 0.1 and FDR-corrected p-values lower than 0.05, using the default parameters for calculation. Allelic specific expression: Allele specific expression was investigated using PHASER[75] on twelve AAA samples with genotype data. Allele specific expression consists of the analysis of the differences in the expression levels of the different haplotypes present in a heterozygous individual. We quantified allele specific expression at the gene level using the GENCODE V26 gene annotation[66]. To reduce the effect of the known mapping bias towards the reference allele[76], we performed an additional STAR mapping step with WASP filtering[77]. We used the allele specific expression data obtained by the GTEx consortium to compare allele specific expression between our AAA samples and GTEx control tissues[78]. To do this, we compared the proportional expression of each allele between our AAA samples and the GTEx

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

controls, using a non-parametric Wilcoxon test [79]. Then, to identify genes with distinct allele specific expression patterns, we corrected for multiple comparisons using FDR[67]. We performed enrichment and cluster analyses in all genes showing FDR adjusted p-values lower than 0.05. **ABBREVIATIONS** AAA abdominal aortic aneurysm **DEGs** differentially expressed genes TABS triple A Barcelona study **LncRNA** long non-coding RNA **TPMs** transcripts per million **PC** principal component GC mean GC mean content **DV200** percentage of RNA fragments > 200 FDR false discovery rate **GO** gene ontology **KEGG** Kyoto encyclopedia of genes **MHC** major histocompatibility complex **GWAS** genome-wide association study ATP adenosine triphosphate **Gsα** heterotrimeric G stimulatory protein **DUSP8** dual specificity phosphatase 8 protein

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

SNP single nucleotide polymorphism MAF minor allele frequency **DECLARATIONS** Ethics approval and consent to participate: The study was approved by the Hospital de la Santa Creu i Sant Pau Ethics Committee (IIBSP-OMI-2019-102). All patients gave written informed consent prior to surgery to participate in the study. The study conformed to the principles of the Declaration of Helsinki. Consent for publication: Not applicable. Availability of data and materials: The personal data used for this study is available from the corresponding author on reasonable request for collaborations provided it complies with the ethical permits of the study. All other data supporting the findings of this study is available within the paper and its Supplementary Information. Code used for data preparation and analysis is available https://github.com/Gerardts9/RNAseq. Competing interests: The authors declare that they have no competing interests. Funding: This work was supported by agrant from the Spanish Ministry of Science and Innovation (PID2019-109844RB-I00). The genotyping service was carried out at the Genotyping Unit-CEGEN in the Spanish National Cancer Research Centre (CNIO), supported by Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación. CEGEN is part of the initiative

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

IMPaCT-GENÓMICA (IMP/00009) cofunded by ISCIII and the European Regional Development Fund (ERDF). GT-S is supported by the Pla Estratègic de Recerca i Innovació en Salut (PERIS) grant from the Catalan Department of Health for junior research personnel (SLT017/20/000100). MS-L is supported by a Miguel Servet contract from the ISCIII Spanish Health Institute (CPII22/00007) and co-financed by the European Social Fund. DD was funded by a Tenovus Scotland Research PhD studentship, T19-06. Author's contributions: AV, MC, and MS-L conceived and designed the study. BS, JD, OP, LC, LN and J-RE generated the clinical database and supplied the samples. GT-S and DD performed the analyses. GT-S, AB, AV, MC, and MS-L interpreted the results. GT-S, AV, MC, and MS-L wrote the manuscript. All authors read and approved the final manuscript. Acknowledgments: We acknowledge the AAA patients at Hospital de la Santa Creu i Sant Pau and Hospital del Mar who participated in this study, and the multiorgan donor families who made this research possible through their generous consent. Author's information: AV, MC, and MS-L contributed equally to this work as senior authors. **REFERENCES** Aggarwal S, Qamar A, Sharma V, Sharma A. Abdominal aortic aneurysm: A comprehensive review. Exp Clin Cardiol 2011;16:11-5. 2. Kuivaniemi H, Ryer EJ, Elmore JR, Tromp G. Understanding the pathogenesis of abdominal aortic aneurysms. Expert Review of Cardiovascular Therapy 2015;13:975-87. Holmes DR, Liao S, Parks WC, Thompson RW. Medial neovascularization in abdominal 3. aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg 1995;21:761–71; discussion 771-772.

- Robinson WP, Schanzer A, Li Y, Goodney PP, Nolan BW, Eslami MH, et al. Derivation and validation of a practical risk score for prediction of mortality after open repair of ruptured abdominal aortic aneurysms in a U.S. regional cohort and comparison to existing scoring systems. J Vasc Surg 2013;57:354–61.
- Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, et al. The
 Society for Vascular Surgery practice guidelines on the care of patients with an abdominal
 aortic aneurysm. Journal of Vascular Surgery 2018;67:2-77.e2.
- Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, et al. The Aneurysm
 Detection and Management Study Screening Program: Validation Cohort and Final
 Results. Archives of Internal Medicine 2000;160:1425–30.
- 7. Roychowdhury T, Klarin D, Levin MG, Spin JM, Rhee YH, Deng A, et al. Genome-wide
 719 association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights
 720 PCSK9 as a therapeutic target. Nat Genet 2023;55:1831–42.
- Lowe R, Shirley N, Bleackley M, Dolan S, Shafee T. Transcriptomics technologies. PLoS
 Comput Biol 2017;13:e1005457.
- 723 9. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat
 724 Rev Genet 2009;10:57–63.
- 725 10. Biros E, Gäbel G, Moran CS, Schreurs C, Lindeman JHN, Walker PJ, et al. Differential gene 726 expression in human abdominal aortic aneurysm and aortic occlusive disease. Oncotarget 727 2015;6:12984–96.
- Lenk GM, Tromp G, Weinsheimer S, Gatalica Z, Berguer R, Kuivaniemi H. Whole genome
 expression profiling reveals a significant role for immune function in human abdominal
 aortic aneurysms. BMC Genomics 2007;8:237.
- 731 12. Biros E, Moran CS, Rush CM, Gäbel G, Schreurs C, Lindeman JHN, et al. Differential gene expression in the proximal neck of human abdominal aortic aneurysm. Atherosclerosis 2014;233:211–8.
- 734 13. Choke E, Cockerill GW, Laing K, Dawson J, Wilson WRW, Loftus IM, et al. Whole Genome 735 expression Profiling Reveals a Role for Immune and Inflammatory Response in Abdominal
 736 Aortic Aneurysm Rupture. European Journal of Vascular and Endovascular Surgery
 737 2009;37:305–10.
- 738 14. Gäbel G, Northoff BH, Weinzierl I, Ludwig S, Hinterseher I, Wilfert W, et al. Molecular
 739 Fingerprint for Terminal Abdominal Aortic Aneurysm Disease. J Am Heart Assoc
 740 2017;6:e006798.
- Tindquist Liljeqvist M, Hultgren R, Bergman O, Villard C, Kronqvist M, Eriksson P, et al.
 Tunica-Specific Transcriptome of Abdominal Aortic Aneurysm and the Effect of
 Intraluminal Thrombus, Smoking, and Diameter Growth Rate. Arteriosclerosis,
 Thrombosis, and Vascular Biology 2020;40:2700–13.
- 745 16. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science
 746 2020;369:1318–30.

- 747 17. Márquez-Sánchez AC, Koltsova EK. Immune and inflammatory mechanisms of abdominal aortic aneurysm. Front Immunol 2022;13:989933.
- 749 18. Yuan Z, Lu Y, Wei J, Wu J, Yang J, Cai Z. Abdominal Aortic Aneurysm: Roles of Inflammatory 750 Cells. Frontiers in Immunology [Internet] 2021 [cited 2022 Jan 25];11. Available from:
- 751 https://www.frontiersin.org/article/10.3389/fimmu.2020.609161
- 752 19. Nie H, Qiu J, Wen S, Zhou W. Combining Bioinformatics Techniques to Study the Key 753 Immune-Related Genes in Abdominal Aortic Aneurysm. Front Genet 2020;11:579215.
- 754 20. Hasimbegovic E, Schweiger V, Kastner N, Spannbauer A, Traxler D, Lukovic D, et al.
 755 Alternative Splicing in Cardiovascular Disease—A Survey of Recent Findings. Genes (Basel)
 756 2021;12:1457.
- 757 21. Rotival M, Quach H, Quintana-Murci L. Defining the genetic and evolutionary architecture 758 of alternative splicing in response to infection. Nat Commun 2019;10:1671.
- 759 22. Romero JP, Ortiz-Estévez M, Muniategui A, Carrancio S, de Miguel FJ, Carazo F, et al.
 760 Comparison of RNA-seq and microarray platforms for splice event detection using a cross761 platform algorithm. BMC Genomics 2018;19:703.
- 762 23. Ouyang M, Wang M, Yu B. Aberrant Mitochondrial Dynamics: An Emerging Pathogenic Driver of Abdominal Aortic Aneurysm. Cardiovasc Ther 2021;2021:6615400.
- 764 24. Summerhill VI, Sukhorukov VN, Eid AH, Nedosugova LV, Sobenin IA, Orekhov AN.
 765 Pathophysiological Aspects of the Development of Abdominal Aortic Aneurysm with a
 766 Special Focus on Mitochondrial Dysfunction and Genetic Associations. Biomolecular
 767 Concepts 2021;12:55–67.
- 768 25. Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV, Orekhov AN. The role of
 769 mitochondrial dysfunction in cardiovascular disease: a brief review. Annals of Medicine
 2018;50:121–7.
- Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, et al. Apelin
 prevents aortic aneurysm formation by inhibiting macrophage inflammation. American
 Journal of Physiology-Heart and Circulatory Physiology 2009;296:H1329–35.
- Shin SJ, Hang HT, Thang BQ, Shimoda T, Sakamoto H, Osaka M, et al. Role of PAR1-Egr1 in
 the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice. Arteriosclerosis,
 Thrombosis, and Vascular Biology 2020;40:1905–17.
- Wang S, Liu H, Yang P, Wang Z, Ye P, Xia J, et al. A role of inflammaging in aortic aneurysm:
 new insights from bioinformatics analysis. Frontiers in Immunology [Internet] 2023 [cited
 2023 Dec 17];14. Available from:
 https://www.frontiersin.org/articles/10.3389/fimmu.2023.1260688
- 781 29. Sung PH, Yang YH, Chiang HJ, Chiang JY, Chen CJ, Liu CT, et al. Risk of aortic aneurysm and dissection in patients with autosomal-dominant polycystic kidney disease: a nationwide population-based cohort study. Oncotarget 2017;8:57594–604.
- 784 30. Kugo H, Moriyama T, Zaima N. The role of perivascular adipose tissue in the appearance of ectopic adipocytes in the abdominal aortic aneurysmal wall. Adipocyte 2019;8:229–39.

or ectopic adipocytes in the abdominar dortic affect young number 2015,0.225 35.

786 31. Chislock EM, Pendergast AM. Abl Family Kinases Regulate Endothelial Barrier Function In Vitro and in Mice. PLoS One 2013;8:e85231.

- 788 32. Beghi S, Furmanik M, Jaminon A, Veltrop R, Rapp N, Wichapong K, et al. Calcium 789 Signalling in Heart and Vessels: Role of Calmodulin and Downstream Calmodulin-
- 790 Dependent Protein Kinases. Int J Mol Sci 2022;23:16139.
- 33. Bround MJ, Wambolt R, Luciani DS, Kulpa JE, Rodrigues B, Brownsey RW, et al.
 Cardiomyocyte ATP Production, Metabolic Flexibility, and Survival Require Calcium Flux
 through Cardiac Ryanodine Receptors in Vivo. J Biol Chem 2013;288:18975–86.
- 794 34. Colotti G, Poser E, Fiorillo A, Genovese I, Chiarini V, Ilari A. Sorcin, a Calcium Binding 795 Protein Involved in the Multidrug Resistance Mechanisms in Cancer Cells. Molecules 796 2014;19:13976–89.
- 797 35. Sanders KM. Invited Review: Mechanisms of calcium handling in smooth muscles.
 798 Journal of Applied Physiology 2001;91:1438–49.
- Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology 2012;1:36.
- 37. Zhang L, Wang Y. B lymphocytes in abdominal aortic aneurysms. Atherosclerosis
 2015;242:311-7.
- 38. Forester ND, Cruickshank SM, Scott DJA, Carding SR. Functional characterization of T cells in abdominal aortic aneurysms. Immunology 2005;115:262–70.
- Sagan A, Mikolajczyk TP, Mrowiecki W, MacRitchie N, Daly K, Meldrum A, et al. T Cells Are
 Dominant Population in Human Abdominal Aortic Aneurysms and Their Infiltration in the
 Perivascular Tissue Correlates With Disease Severity. Frontiers in Immunology [Internet]
 2019 [cited 2024 Feb 9];10. Available from:
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01979
- 40. Xiong T, Lv XS, Wu GJ, Guo YX, Liu C, Hou FX, et al. Single-Cell Sequencing Analysis and
 Multiple Machine Learning Methods Identified G0S2 and HPSE as Novel Biomarkers for
 Abdominal Aortic Aneurysm. Front Immunol 2022;13:907309.
- Ferreira PG, Muñoz-Aguirre M, Reverter F, Sá Godinho CP, Sousa A, Amadoz A, et al. The effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nat Commun 2018;9:490.
- Forester ND, Cruickshank SM, Scott DJA, Carding SR. Increased natural killer cell activity in patients with an abdominal aortic aneurysm. British Journal of Surgery 2006;93:46–54.
- 43. Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, et al. Association
 819 Between Osteopontin and Human Abdominal Aortic Aneurysm. Arteriosclerosis,
 820 Thrombosis, and Vascular Biology 2007;27:655–60.
- 821 44. Black KM, Masuzawa A, Hagberg RC, Khabbaz KR, Trovato ME, Rettagliati VM, et al.
 822 Preliminary Biomarkers for Identification of Human Ascending Thoracic Aortic Aneurysm.

823 J Am Heart Assoc 2013;2:e000138.

824 45. Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. 825 Clinical Biochemistry 2018;59:17–24. 826 46. Wang SK, Green LA, Gutwein AR, Gupta AK, Babbey CM, Motaganahalli RL, et al. 827 Osteopontin may be a driver of abdominal aortic aneurysm formation. Journal of Vascular 828 Surgery 2018;68:22S-29S. 829 47. Liu H, Zhang Y, Song W, Sun Y, Jiang Y. Osteopontin N-Terminal Function in an Abdominal 830 Aortic Aneurysm From Apolipoprotein E-Deficient Mice. Frontiers in Cell and 831 Developmental Biology [Internet] 2021 [cited 2023 Nov 22];9. Available from: 832 https://www.frontiersin.org/articles/10.3389/fcell.2021.681790 833 Qin X, He L, Tian M, Hu P, Yang J, Lu H, et al. Smooth muscle-specific Gsα deletion 834 exaggerates angiotensin II-induced abdominal aortic aneurysm formation in mice in vivo. 835 J Mol Cell Cardiol 2019;132:49-59. 836 Zhang R, Ji Z, Yao Y, Zuo W, Yang M, Qu Y, et al. Identification of hub genes in unstable 837 atherosclerotic plague by conjoint analysis of bioinformatics. Life Sciences 838 2020;262:118517. 839 Greene D, Pirri D, Frudd K, Sackey E, Al-Owain M, Giese APJ, et al. Genetic association 840 analysis of 77,539 genomes reveals rare disease etiologies. Nat Med 2023;29:679-88. 841 Kobeissi E, Hibino M, Pan H, Aune D. Blood pressure, hypertension and the risk of 842 abdominal aortic aneurysms: a systematic review and meta-analysis of cohort studies. 843 Eur J Epidemiol 2019;34:547-55. 844 52. Wang B, Cai W, Ai D, Zhang X, Yao L. The Role of Deubiquitinases in Vascular Diseases. J. of 845 Cardiovasc. Trans. Res. 2020;13:131-41. 846 Johnson M. Molecular mechanisms of β2-adrenergic receptor function, response, and 847 regulation. Journal of Allergy and Clinical Immunology 2006;117:18–24. 848 Ding T, Zhou Y, Long R, Chen C, Zhao J, Cui P, et al. DUSP8 phosphatase: structure, 849 functions, expression regulation and the role in human diseases. Cell & Bioscience 850 2019;9:70. 851 Baldo G, Wu S, Howe RA, Ramamoothy M, Knutsen RH, Fang J, et al. Pathogenesis of 852 aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. 853 Mol Genet Metab 2011;104:608-19. 854 56. Emery P, Durand B, Mach B, Reith W. RFX proteins, a novel family of DNA binding proteins 855 conserved in the eukaryotic kingdom. Nucleic Acids Res 1996;24:803-7. 856 Liu Y, Wang X, Wang H, Hu T. Identification of key genes and pathways in abdominal aortic 857 aneurysm by integrated bioinformatics analysis. J Int Med Res 858 2020;48:0300060519894437. 859 Du P, Gao K, Cao Y, Yang S, Wang Y, Guo R, et al. RFX1 downregulation contributes to TLR4 860 overexpression in CD14+ monocytes via epigenetic mechanisms in coronary artery 861 disease. Clin Epigenetics 2019;11:44.

disease. Clin Epigenetics 2019;11:44.

862 Blomkalns AL, Gavrila D, Thomas M, Neltner BS, Blanco VM, Benjamin SB, et al. CD14 863 Directs Adventitial Macrophage Precursor Recruitment: Role in Early Abdominal Aortic 864 Aneurysm Formation. J Am Heart Assoc 2013;2:e000065. 865 An imprinted, mammalian bicistronic transcript encodes two independent proteins 866 PNAS [Internet]. [cited 2024 Feb 12]; Available from: 867 https://www.pnas.org/doi/10.1073/pnas.96.10.5616 868 Zhang K, Li M, Yin L, Fu G, Liu Z. Role of thrombospondin-1 and thrombospondin-2 in 869 cardiovascular diseases (Review). Int J Mol Med 2020;45:1275-93. 870 Liu Z, Morgan S, Ren J, Wang Q, Annis DS, Mosher DF, et al. Thrombospondin-1 (TSP1) 871 Contributes to the Development of Vascular Inflammation by Regulating Monocytic Cell 872 Motility in Mouse Models of Abdominal Aortic Aneurysm. Circulation Research 873 2015;117:129-41. 874 63. Wang C, Gong B, Bushel PR, Thierry-Mieg J, Thierry-Mieg D, Xu J, et al. A comprehensive 875 study design reveals treatment- and transcript abundance-dependent concordance 876 between RNA-seq and microarray data. Nat Biotechnol 2014;32:926-32. 877 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast 878 universal RNA-seg aligner. Bioinformatics 2013;29:15–21. 879 Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or 880 without a reference genome. BMC Bioinformatics 2011;12:323. 881 Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: 882 The reference human genome annotation for The ENCODE Project. Genome Res 883 2012;22:1760-74. 884 Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful 885 Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B 886 (Methodological) 1995;57:289-300. 887 68. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R Package for Comparing Biological 888 Themes Among Gene Clusters. OMICS 2012;16:284–7. 889 Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set 890 enrichment analysis: A knowledge-based approach for interpreting genome-wide 891 expression profiles. Proceedings of the National Academy of Sciences 2005;102:15545-892 50. 893 KEGG: new perspectives on genomes, pathways, diseases and drugs | Nucleic Acids 894 Research | Oxford Academic [Internet]. [cited 2023 Apr 27]; Available from: 895 https://academic.oup.com/nar/article/45/D1/D353/2605697 896 Storey JD. A Direct Approach to False Discovery Rates. Journal of the Royal Statistical 897 Society. Series B (Statistical Methodology) 2002;64:479–98. 898 Kerseviciute I, Gordevicius J. aPEAR: an R package for autonomous visualization of 899 pathway enrichment networks. Bioinformatics 2023;39:btad672.

900 73. Yu G, Hu E, Gao CH. enrichplot: Visualization of Functional Enrichment Result [Internet]. 901 2023 [cited 2023 Nov 21]; Available from: https://bioconductor.org/packages/enrichplot/ 902 Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating 903 immune cells with CIBERSORT. Methods Mol Biol 2018;1711:243-59. 904 Castel SE, Mohammadi P, Chung WK, Shen Y, Lappalainen T. Rare variant phasing and 905 haplotypic expression from RNA sequencing with phASER. Nat Commun 2016;7:12817. 906 Degner JF, Marioni JC, Pai AA, Pickrell JK, Nkadori E, Gilad Y, et al. Effect of read-mapping 907 biases on detecting allele-specific expression from RNA-sequencing data. Bioinformatics 908 2009;25:3207-12. 909 van de Geijn B, McVicker G, Gilad Y, Pritchard JK. WASP: allele-specific software for robust 910 molecular quantitative trait locus discovery. Nat Methods 2015;12:1061–3. 911 Castel SE, Aguet F, Mohammadi P, Aguet F, Anand S, Ardlie KG, et al. A vast resource of 912 allelic expression data spanning human tissues. Genome Biology 2020;21:234. 913 van Beek D, Verdonschot J, Derks K, Brunner H, de Kok TM, Arts ICW, et al. Allele-specific 914 expression analysis for complex genetic phenotypes applied to a unique dilated 915 cardiomyopathy cohort. Sci Rep 2023;13:564. 916 FIGURE LEGENDS 917 Figure 1 918 Study design flowchart. 919 Figure 2 920 Hierarchical clustering analysis results with all the DEGs between AAA and controls (A) and 921 after removing DEG by ischemic time (B). C) Comparison of the proportion of inflammatory 922 cells between AAA and controls using CIBERSORTx. 923 Figure 3 924 A) Significant alternative splicing types identified between AAA and controls. B) Venn diagram 925 showing the overlap between DEGs in AAA and controls and genes with differential alternative 926 splicing patterns in AAA and controls. C) Venn diagram showing the overlap between DEGs in 927 AAA and controls and DEGs by AAA diameter. 928 Figure 4

36

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946


947


948

949

A) Results of PC analysis clustering between AAA and controls. B) Hierarchical clustering analysis results with genes with different allelic specific patterns between AAA and controls. SUPPLEMENTARY INFORMATION Additional file 1: Figures S1-S6 Contains Supplementary Figures S1-S6. Additional file 2: Table S1 Complete differential expression results between AAA and controls. Additional file 3: Table S2 GO functional enrichment analysis results between AAA and controls (including genes affected by ischemic time). Additional file 4: Table S3 KEGG functional enrichment analysis results between AAA and controls (including genes affected by ischemic time). Additional file 5: Table S4 Differential expressed genes by ischemic time in GTEx samples. Additional file 6: Table S5 GO functional enrichment analysis results between AAA and controls (excluding genes affected by ischemic time). Additional file 7: Table S6 KEGG functional enrichment analysis results between AAA and controls (excluding genes affected by ischemic time).

950 Additional file 8: Table S7
951 Results of the alternative splicing study between AAA and controls.
952 Additional file 9: Table S8
953 Complete differential expression results between AAA of different diameter.
954 Additional file 10: Table S9
955 Correlation analysis between biological and technical covariates.





A)

